Clinical trial NCT01987609: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Official title: Evaluation of the Effect of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Psoriasis
Keywords: Psoriasis
Dendritic cells
Hyaluronidase
Hylenex
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2013-11-19
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dendritic cells are a key component of the inflammatory response seen in psoriasis. Several current psoriasis therapies have been shown to reduce the number of dendritic cells in patients with psoriasis, leading researchers to believe that therapies specifically targeting dendritic cells may lead to improvement in psoriasis. Research recently conducted in Dr. Gallo's lab at the University of California San Diego has shown that transgenic mice overexpressing the enzyme hyaluronidase have a significant decrease in the number of dendritic cells in the dermal component of their skin compared to wild type mice. If hyaluronidase overexpression in humans also decreases the number of dendritic cells in the dermis, then hyaluronidase therapy may improve the clinical presentation of psoriasis. In order to test this hypothesis, recombinant human hyaluronidase (Hylenex®) will be injected subcutaneously below a psoriatic plaque in human psoriasis patients every week for a total of 4 weeks. Each week the clinical appearance of the plaque will be documented. At the final visit skin biopsies of the treated plaque will be taken to visualize the histology of the plaque and look for changes in expression of different inflammatory markers.

Detailed description: Participation in this study will consist of a total of 5 visits to the UCSD Dermatology Clinic over approximately a one-month period. At the first visit, two psoriatic plaques between 2-cm and 5-cm in diameter to be studied in this trial will be agreed upon by the patient as well as the blinded and unblinded investigators. Preference will be given to plaques on the elbows since the elbow is a common place of psoriatic plaques, and since scarring on the elbows is usually more acceptable than scarring on other parts of the skin since the skin on the elbows is naturally hyperpigmented in most people. For the remainder of the study, all grading and measurements of the psoriatic plaques will be completed by a blinded investigator who is unaware of which plaque is receiving which treatment. An unblinded investigator will complete all other portions of the study visit, including digital photography, injecting the plaques, and completing the biopsies. The subject will also be blinded as to which plaque is being injected with which treatment.

During the first 4 visits, plaques will be injected with 1-mL of Hylenex® or 1-mL of sterile (pharmaceutical grade) normal saline (NS). 1-mL of Hylenex® contains 150 Units of recombinant hyaluronidase. This is the standard dose of the drug that has been approved by the FDA, and therefore this dose is considered to be safe for use in adults. If injected subcutaneously into the center of a psoriatic plaque that is between 2 and 5 centimeters in diameter, this 1-mL dose should be able to diffuse throughout the entire area beneath the plaque. The exact pharmacokinetics of Hylenex® are difficult to study due to its rapid inactivation after intravenous injection. According to the Hylenex® package insert, though, disruptions to the dermal barrier that occur in response to subcutaneous Hylenex® injection persist 24 hours after injection, but this barrier is completely restored after 48 hours. Cutaneous dendritic cells residing in the epidermis are thought to migrate away from the epidermis through either lymphatic or vascular channels after Hylenex® is injected. This process should take a few hours. Since cutaneous dendritic cells are thought to turnover only every several weeks, new dendritic cells should not populate the epidermis before patients receive the next injection of Hylenex®. Since dendritic cell activation initiates the inflammatory cascade thought to result in psoriasis, preventing dendritic cells from being harbored in the epidermis should essentially prevent the inflammatory cascade that results in psoriasis. Therefore, during the month-long period while patients are receiving Hylenex® injections, the inflammatory cascade triggering their psoriasis will potentially be turned off, allowing affected plaques to heal without propagation of further psoriasis. If this is true, there should be differences in the Hylenex®-treated versus the NS-treated plaques both morphologically and histologically upon completion of the final set of biopsies on the Visit 5.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of plaque psoriasis for at least 6 months, with at least 2 psoriatic plaques on different parts of the body that are both between 2-cm and 5-cm in diameter at the time of screening
* Age 18-65 years
* Male subjects who agree to use barrier methods for contraception throughout the course of the trial if their female partners are of child-bearing potential, or female subjects not of child-bearing potential
* Subject agrees to comply with study requirements
* Subject is fluent in English and is able to provide written informed consent

Exclusion Criteria:

* Subjects with severe medical condition(s) that in the view of the investigator prohibits participation in the study
* Subject has Netherton's syndrome or other genodermatoses that result in a defective epidermal barrier
* Subjects who have applied topical medications (prescription or over-the-counter) for the treatment of psoriasis to their body within 7 days of the baseline visit
* Subjects who have taken cyclosporine, methotrexate, immuran, oral retinoids, chemotherapeutic agents, anti-inflammatory biologics (e.g., alefacept, etanercept, etc.), or oral calcineurin inhibitors within 28 days of the baseline visit
* Subjects who are unable to hold their current psoriasis medications for the period of time indicated (at least 7 days for topical medications, at least 28 days for oral or injectable medications) without significant worsening of their psoriasis
* Immunocompromised subjects (e.g., lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome), or subjects with a history of malignant disease (excluding non-melanoma skin cancer) as determined by the participant's medical history.
* Subjects receiving phototherapy (e.g., ultraviolet light B \[UVB\], psoralen plus ultraviolet light A \[PUVA\]) within 28 days of the baseline visit
* Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol
* Subjects with significant concurrent medical condition(s) at screening that in the view of the investigator prohibits participation in the study (e.g., severe concurrent allergic disease, condition associated with malignancy, and condition associated with immunosuppression)
* Subjects who have used any systemic antibiotics within 28 days of the baseline visit
* Subjects with an active bacterial, viral or fungal skin infection (excluding nail fungus)
* Subjects currently receiving lithium or have received lithium within the last 4 weeks.
* Ongoing participation in an investigational drug trial
* Subjects with diabetes requiring medication
* Presence of psoriasis with exfoliative erythroderma or presence of guttate psoriasis, primary palmoplantar psoriasis, or pustular psoriasis
* Hypersensitivity to hyaluronidase or any other ingredient in the formulation of hyaluronidase, as well as subjects with an allergy or hypersensitivity to lidocaine
* Subjects taking furosemide, benzodiazepines, phenytoin, salicylates, cortisone, antihistamines or estrogens

Primary outcomes:
measure: Psoriasis Area Severity Index
timeFrame: 4 weeks
Secondary outcomes:
measure: Plaque Area
timeFrame: 4 weeks
measure: Plaque Area
timeFrame: 2 weeks
measure: Plaque Area
timeFrame: 3 weeks
measure: Plaque Area
timeFrame: 1 weeks
measure: Physician Global Assessment (PGA)
timeFrame: 3 weeks
measure: Physician Global Assessment (PGA)
timeFrame: 2 weeks
measure: Physician Global Assessment (PGA)
timeFrame: 1 week
measure: Change in Histologic Appearance of Psoriatic Plaques
timeFrame: baseline and 4 weeks
measure: Change in Tumor Necrosis Factor Alpha (TNFα) Expression
timeFrame: 4 weeks
measure: Change in Interferon Alpha (IFNα) Expression
timeFrame: 4 weeks
measure: Change in Toll-like Receptor 7 (TLR-7) Expression
timeFrame: 4 weeks
measure: Change in Toll-like Receptor 8 (TLR-8) Expression
timeFrame: 4 weeks
measure: Change in Toll-like Receptor 9 (TLR-9) Expression
timeFrame: 4 weeks
Other outcomes:
measure: Adverse Events
timeFrame: 1 week
measure: Adverse Events
timeFrame: 2 weeks
measure: Adverse Events
timeFrame: 3 weeks
Locations:
city: San Diego
country: United States
facility: UCSD Division of Dermatology
state: California
Study officials:
affiliation: UCSD Division of Dermatology
name: Tissa Hata, MD
role: PRINCIPAL_INVESTIGATOR
References: